Therefore, with the intention of evaluating the potential therapeutic value of pan-PI3K inhibition in AML, we have designed various assays to survey the antitumor impacts and molecular mechanisms underlying the action of BKM120 for treatment of AML. This evidence concerns the gene PIK3CA and acute myeloid leukemia.